Sucheta Telang
Affiliations: | University of Louisville, Louisville, KY, United States |
Area:
Biochemistry, Molecular BiologyGoogle:
"Sucheta Telang"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lypova N, Telang S, Chesney J, et al. (2019) Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival. The Journal of Biological Chemistry |
| Vanherwegen AS, Eelen G, Bomfim Ferreira G, et al. (2018) Vitamin D controls the capacity of human dendritic cells to induce functional regulatory T cells by regulation of glucose metabolism. The Journal of Steroid Biochemistry and Molecular Biology |
| Mondal S, Roy D, Sarkar Bhattacharya S, et al. (2018) Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. International Journal of Cancer |
| Chesney J, Imbert-Fernandez Y, Telang S, et al. (2018) Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Research |
| Chesney J, Mojesky A, Imbert-Fernandez Y, et al. (2018) Abstract 5487: Targeting glycolysis for the treatment of cancer Cancer Research. 78: 5487-5487 |
| Imbert-Fernandez Y, Lanceta L, Telang S, et al. (2018) Abstract 2305: Targeting 6-phosphofructo-2-kinase to increase the efficacy of ER and CDK4/6 inhibitors against breast cancer Cancer Research. 78: 2305-2305 |
| Grewal JS, Al-Rayyan N, Ritchie J, et al. (2017) Targeting the glucose metabolism of monocytic myeloid-derived suppressor cells to stimulate cancer immunity. Journal of Clinical Oncology. 35: 126-126 |
| O'Neal J, Clem A, Reynolds L, et al. (2016) Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Research and Treatment |
| Clem BF, O'Neal J, Klarer AC, et al. (2016) Clinical development of cancer therapeutics that target metabolism. Qjm : Monthly Journal of the Association of Physicians. 109: 367-72 |
| Chesney JA, Telang S, Yaddanapudi K, et al. (2016) Targeting 6-phosphofructo-2-kinase (PFKFB3) as an immunotherapeutic strategy. Journal of Clinical Oncology. 34 |